Curis Inc. (NASDAQ:CRIS) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the company. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $5.00.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Friday, July 8th. Robert W. Baird restated an “outperform” rating and issued a $7.00 target price on shares of Curis in a report on Friday, June 3rd. Finally, FBR & Co restated a “buy” rating on shares of Curis in a report on Monday, June 13th.

Curis (NASDAQ:CRIS) opened at 2.36 on Monday. The stock’s market cap is $305.55 million. The firm has a 50-day moving average of $1.82 and a 200-day moving average of $1.74. Curis has a 12-month low of $1.25 and a 12-month high of $3.18.

Curis (NASDAQ:CRIS) last issued its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. During the same quarter in the prior year, the business posted ($0.06) EPS. The company’s revenue for the quarter was down 19.0% on a year-over-year basis. Equities analysts predict that Curis will post ($0.38) earnings per share for the current fiscal year.

In other Curis news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average price of $2.40 per share, for a total transaction of $24,499,999.20. Following the purchase, the insider now directly owns 27,328,464 shares in the company, valued at $65,588,313.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.09% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Teachers Advisors Inc. boosted its stake in shares of Curis by 11.5% in the second quarter. Teachers Advisors Inc. now owns 180,776 shares of the company’s stock worth $282,000 after buying an additional 18,634 shares in the last quarter. TFS Capital LLC boosted its stake in shares of Curis by 92.4% in the second quarter. TFS Capital LLC now owns 425,243 shares of the company’s stock worth $663,000 after buying an additional 204,278 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Curis during the second quarter worth $310,000. BlackRock Fund Advisors boosted its stake in shares of Curis by 0.7% in the second quarter. BlackRock Fund Advisors now owns 4,585,732 shares of the company’s stock worth $7,154,000 after buying an additional 30,324 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its stake in shares of Curis by 6.2% in the second quarter. BlackRock Investment Management LLC now owns 418,312 shares of the company’s stock worth $653,000 after buying an additional 24,489 shares in the last quarter. Hedge funds and other institutional investors own 52.36% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.